• Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis

    7 days ago - By Xconomy

    Biogen is bolstering its strategy of selling biosimilars-lower-cost versions of biological drugs that are losing patent protection-with a $100 million deal for rights to two eye products. The drug maker is also expanding its biosimilar scope to include China. Cambridge, MA-based Biogen struck the deal with Samsung Bioepis, its joint venture with Samsung BioLogics of South Korea. Under the agreement announced Wednesday, Biogen will pay Samsung Bioepis $100 million up front for the rights to SB11, a drug that's biologically similar to Roche's drug ranibizumab ; and SB15, which references the...
    Read more ...